Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, has released its financial results for the second quarter of 2025. The company reported a net loss of $99.7 million for the period. Research and development expenses reached $80.9 million, while general and administrative expenses were $23.7 million. As of June 30, 2025, Nuvalent's cash, cash equivalents, and marketable securities totaled $1.0 billion, with the company projecting this cash position will be sufficient to fund its operating plan into 2028. In terms of business operations, Nuvalent announced the promotion of Jason Waters to Senior Vice President, Commercial, to support the company's transition towards becoming a fully integrated, commercial-stage biopharmaceutical organization. The company also highlighted several key pipeline achievements, including the initiation of a rolling NDA submission for zidesamtinib for advanced ROS1-positive NSCLC and the start of the ALKAZAR Phase 3 trial for neladalkib in front-line ALK-positive NSCLC. Preliminary data on neladalkib will be presented at the ESMO Congress 2025, with topline pivotal data expected by year-end 2025.